IL3RA and acute myeloid leukemia: The observed response of patients with PIF/ER AML to CD123-targeted immunotherapy is in accordance with the finding that an immune-infiltrated (IFN-γ–dominant) tumour microenvironment can identify patients who are less likely to respond to cytotoxic chemotherapy but more likely to respond to immunotherapy [74].